Bemotrizinol

Summary

Bemotrizinol (CHEMBL2104956) is a phase-3 clinical-stage small molecule; indicated across 1 condition including sunburn.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 627.8 Da · C38H49N3O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104956
Name	Bemotrizinol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	135487856
Molecular formula	C38H49N3O5
Molecular weight	627.8
InChIKey	XVAMCHGMPYWHNL-UHFFFAOYSA-N

SMILES: CCCCC(CC)COC1=CC(=C(C=C1)C2=NC(=NC(=N2)C3=CC=C(C=C3)OC)C4=C(C=C(C=C4)OCC(CC)CCCC)O)O

IUPAC name: 5-(2-ethylhexoxy)-2-[4-[4-(2-ethylhexoxy)-2-hydroxyphenyl]-6-(4-methoxyphenyl)-1,3,5-triazin-2-yl]phenol

Also known as: Bemotrizinol, BEMT, FAT 70'884, FAT-70884, NSC-759870, Tinosorb s, BEMOTRIZINOL

Patent coverage: 2,891 distinct patent families (6,920 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 6,344 (92%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
sunburn	2	MONDO:0005326	EFO:0003958

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05277376	PHASE3	COMPLETED	Pharmacokinetic (PK) Evaluation of Bemotrizinol (6%) in a Sunscreen Maximum Usage Trial
NCT04355286	PHASE1	COMPLETED	Bemotrizinol UV Filter Part 1 Clinical PK Evaluation in Topical MUsT Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).